Akero Therapeutics, Inc (AKRO)

Etorro trading 970x250

About Akero Therapeutics, Inc

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Akero Therapeutics, Inc News and around…

Latest news about Akero Therapeutics, Inc (AKRO) common stock and company :

Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
04 Aug, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported second quarter financial results for the period ending June 30, 2022 and provided business updates. “During the second quarter of this year we took important steps toward optimizing our capital structure to support the ongoing developmen

Analysts Anticipate 19% Upside For The Holdings of SMLV
19 Jul, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR SSGA US Small Cap Low Volatility Index ETF (SMLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $124.04 per unit.

This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations
11 Jul, 2022 FinancialContent

In June,89bio Inc(NASDAQ: ETNB)announced topline resultsfrom the ENTRIGUE Phase 2 proof-of-concept study of ...

Akero Therapeutics Presents Analysis at the 2022 International Liver Congress Showing that Efruxifermin Improved Histopathology and Markers of Liver Injury Across PNPLA3 Genotypes in Patients with NASH Fibrosis
27 Jun, 2022 Yahoo! Finance

Post hoc analysis shows potential for EFX to treat patients at highest genetic risk for progressive and advanced NASHSOUTH SAN FRANCISCO, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced the presentation of an analysis from its Phase 2a BALANCED study of efruxifermin (EFX) in patients with biopsy-confirme

89 Biggest Movers From Friday
21 Jun, 2022 FinancialContent

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 ...

63 Biggest Movers From Yesterday
17 Jun, 2022 FinancialContent

Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company ...

Akero Therapeutics Shares Surge After Equity Investment From This Famed Large Cap Biopharma
16 Jun, 2022 FinancialContent

Akero Therapeutics Inc(NASDAQ: AKRO) announced a$25 million equity investmentbyPfizer Inc(NYSE: PFE) at ...

Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million
16 Jun, 2022 Yahoo! Finance

$25 Million Equity Investment by Pfizer at $9.90 Per Share Term Loan Facility from Hercules Providing Up to $100 Million If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024 SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced two financing

The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data
15 Jun, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pfizer Halts Enrollment In ...

Surprising Analyst 12-Month Target For SMLV
14 Jun, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the SPDR SSGA US Small Cap Low Volatility Index ETF (SMLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $126.42 per unit.

Akero Therapeutics to Present at Keystone Symposium on Efruxifermin as a Therapy for NASH
13 Jun, 2022 Yahoo! Finance

Presentations to highlight the association of EFX’s antifibrotic effects as scored by histology with consistent reductions in biomarkers of liver collagen synthesisSOUTH SAN FRANCISCO, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it will present oral and poster presentations at the Keystone Sympo

Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
01 Jun, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Thursday, June 9, 2022, at 4:00 p.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of the Company's

Analysts Anticipate VTWG Will Reach $246
12 May, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Growth ETF (VTWG), we found that the implied analyst target price for the ETF based upon its underlying holdings is $246.27 per unit.

Akero Therapeutics: Q1 Earnings Insights
06 May, 2022 FinancialContent

Akero Therapeutics (NASDAQ:AKRO) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what ...

Akero Therapeutics Reports First Quarter 2022 Financial Results
06 May, 2022 Yahoo! Finance

Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This YearSOUTH SAN FRANCISCO, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported first quarter financial results for the period ending March 31, 2022. “Our dedicated team continues to advance our two Phase 2b clinical tria

Akero Therapeutics to Present at Upcoming Healthcare Conferences in May
02 May, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, May 02, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in the following investor conferences this month: BofA Securities 2022 Healthcare Conference: Fireside chat on Wednesday, May 11 at 8:40 a.m. PT. in Las Vegas, Nevada.H.C. Wainwright Annual Global Life Sciences C

Akero Therapeutics is Now Oversold (AKRO)
08 Mar, 2022 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

We're Hopeful That Akero Therapeutics (NASDAQ:AKRO) Will Use Its Cash Wisely
07 Mar, 2022 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Akero Therapeutics: Q4 Earnings Insights
25 Feb, 2022 FinancialContent

Akero Therapeutics (NASDAQ:AKRO) reported its Q4 earnings results on Friday, February 25, 2022 at 08:00 AM. Here's what ...

Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
25 Feb, 2022 Yahoo! Finance

Akero Remains on Track to Report Phase 2b HARMONY Study Results in the Third Quarter of This YearSOUTH SAN FRANCISCO, Calif., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported fourth quarter and full year financial results for the period ending December 31, 2021. "Our confidence in efruxifermin’s (EFX’s) potential

Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients
08 Feb, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that it has completed enrollment of the Phase 2b HARMONY study of efruxifermin (EFX), a novel FGF21 analog, for the treatment of non-alcoholic steatohepatitis (NASH). "We believe EFX has the potential, if approved, to become a leading t

The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
04 Feb, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Valneva, Pfizer Announces ...

Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?
14 Jan, 2022 Yahoo! Finance

Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Look Under The Hood: VTWV Has 18% Upside
12 Jan, 2022 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 Value ETF (VTWV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $172.55 per unit.

Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 Jan, 2022 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11 at 10:30 a.m. E.T. A live webcast of the Company presentation will be available through the investor relations section of the Compa

Analysts Forecast 35% Upside For The Holdings of BIB
09 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $111.17 per unit.

Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference
26 Nov, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Virtual Conference on Thursday December 2 at 3:30 p.m. E.T. A live webcast of the Company fireside chat will be available through the investor relatio

Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a Bet
17 Nov, 2021 Yahoo! Finance

The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 91.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment
12 Nov, 2021 Yahoo! Finance

Most EFX-treated patients with end-of-treatment biopsies showed improvements in features of steatohepatitis (35 of 40; 87%) and/or fibrosis (32 of 40; 80%), after only 16 weeks Histological improvements were evident across all types of patients, including those at higher risk of progressing to advanced stages of NASH SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatmen

Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
12 Nov, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today reported third quarter financial results for the period ending September 30, 2021. “Our team remains focused on successfully completing two Phase 2b clinical trials, and diligently working with regulators to bring efruxifermin (EFX) to market, potentially as a treatme

Akero Therapeutics, Inc (AKRO) is a NASDAQ Common Stock listed in , ,

970x250